Patent ID: 8084261
Filing Date: 2011-12-27
Classification: A61P,G01N

Abstract:
1. A method of predicting responsiveness to treatment for obesity or overweight in a human with a pharmaceutical agent selected from the group consisting of a serotonin 5-HT 2C receptor agonist, a cannabinoid-1 receptor (CB-1) antagonist, a phospholipid diesterase-10 (PDE-10) inhibitor, an orexin-1 antagonist, a serotonin-noradrenaline-dopamine triple reuptake inhibitor (SNDRI), a lipase inhibitor, and/or a lipid absorption receptor inhibitor, comprising determining in the human whether there is a significant reduction in triglyceride rich lipoprotein (TRL) V6 response to a fat load in the presence of the pharmaceutical agent compared to the TRL V6 response to a fat load in the absence of the pharmaceutical agent.